CN Patent

CN103282020B — 用于递送治疗剂的可生物侵蚀的硅基装置

Assigned to Viewpoint Pharmaceutical Co Ltd · Expires 2016-10-26 · 10y expired

What this patent protects

本发明公开了用于以受控方式递送治疗剂尤其是诸如蛋白质和抗体的大分子的可生物侵蚀的装置，诸如植入物。所述装置包含用所述治疗剂浸渍的多孔硅基载体材料。所述装置可在体外或体内用于递送所述治疗剂，优选地以受控方式递送一段预期的时间，诸如数日、数周或数月。所述装置可用于治疗或预防患者的疾患，诸如慢性疾病。

USPTO Abstract

本发明公开了用于以受控方式递送治疗剂尤其是诸如蛋白质和抗体的大分子的可生物侵蚀的装置，诸如植入物。所述装置包含用所述治疗剂浸渍的多孔硅基载体材料。所述装置可在体外或体内用于递送所述治疗剂，优选地以受控方式递送一段预期的时间，诸如数日、数周或数月。所述装置可用于治疗或预防患者的疾患，诸如慢性疾病。

Drugs covered by this patent

bendamustine-hydrochloride (BENDAMUSTINE HYDROCHLORIDE)

Patent Metadata

Patent number: CN103282020B
Jurisdiction: CN
Classification: —
Expires: 2016-10-26
Drug substance claim: No
Drug product claim: No
Assignee: Viewpoint Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.